PV QA 4 - Poster Viewing Q&A 4
Purpose/Objective(s): To study the objective effective rate, survival and safety of radiotherapy combined with Irassa for patients with locally advanced non-small cell lung cancer (NSCLC) who couldn’t receive surgery or concurrent chemoradiotherapy.
Materials/Methods: The patients with the locally advanced NSCLC who couldn’t receive surgery or concurrent chemoradiotherapy, received thoracic intensity modulated radiotherapy (IMRT) combined with gefitinib 250mg daily.
Results: A total of 30 patients were registered between July 2014 and March 2017. Twenty-nine patients were analyzed. One month after radiotherapy, the response rates included completely response (CR) 0, partial response (PR) 21 (72.4%) , stable disease(SD) 6(20.7%), progressive disease(PD) 2(6.9%), the disease control rate (CR+PR+SD) was 93.1%, and the objective effective rate was 72.4%. The last follow-up time was December 15, 2017, the median follow-up time was 25 months. Fourteen (48.3%) patients were dead, and fifteen (51.7%) alive. The disease progression showed in 23(79.3%) patients, including local progression in 18 (62.1%) and distant metastasis in 14 (48.3%). The median survival time (MST) was 26 months, the median PFS was 11 months. The 1-year OS and PFS were 78.9% and 43.5%, the 2-year OS and PFS were 55.1% and 17.5%. Univariate analysis showed that smoking history, disease stage and disease progression were influencing factors for OS. Univariate analysis showed that disease stage, the primary tumor diameter, the volume of GTV and PTV were influencing factors for PFS. Multivariable analysis showed that disease stage and the volume of PTV were independent prognostic factors for PFS. Patients with stage ⅢB had better OS and PFS than stage ⅢA. No≥ grade 4 acute adverse events were observed, and two patients developed grade 3 acute adverse events, two developed grade 2 acute irradiation pneumonitis , no≥ grade 3 acute irradiation pneumonitis.
Conclusion: For patients with locally advanced NSCLC who couldn’t receive surgery or concurrent chemoradiotherapy, IMRT combined with Irassa show higher the objective effective rate and well tolerated. The further effect needs observation.
The asset you are trying to access is locked. Please enter your access key to unlock.